MedClinic Partners Blog: Compliance & Industry Insights
Compliance & Industry Insights
Expert guidance on 503A/503B compounding regulations, GLP's supply, clinic M&A, and what's changing in medical practice law — written by attorneys and operators who've been in the space.
All Posts
95 articles · Page 1 of 11
Competitive Positioning: Using Next-Gen Peptides to Differentiate Your Practice
Thoughtful engagement with next-generation therapies like retatrutide can become a meaningful point of distinction — but only when executed with compliance discipline and genuine patient education.
How Retatrutide Fits Into Healthspan and Longevity Medicine Programs
Many practices are expanding from weight management into broader healthspan programs. Retatrutide can play a meaningful role when integrated thoughtfully — here is how to position it correctly.
Retatrutide and the Evolution of Triple-Agonist Therapy: Strategic Implications for Clinics
Retatrutide represents a significant step forward in metabolic therapy as a triple agonist. For clinic owners thinking strategically about where the field is heading, here are the implications.
Building Defensible Compliance Around Retatrutide to Maximize Sale Price
Strong, defensible compliance systems around investigational therapies protect current operations and can positively influence practice value at exit. Here is what that infrastructure looks like.
What M&A Buyers Are Asking About Next-Generation Peptide Programs in 2026
During due diligence in 2026, sophisticated buyers are asking increasingly specific questions about how practices have engaged with investigational metabolic therapies. Here is what they want to know.
How Offering Retatrutide Impacts Practice Valuation at Exit
Offering access to investigational compounds like retatrutide can influence practice valuation in both positive and negative ways — depending entirely on how the program is structured and documented.
GLP's Dosing and Titration Protocols: A Clinical Reference
Proper titration is critical for GLP's tolerability and outcomes. Here is a clinical reference for dosing and titration protocols for semaglutide, tirzepatide, and retatrutide.
Preparing Your Practice for Retatrutide FDA Approval: What the Timeline Looks Like and How to Position Now
Retatrutide is on track for FDA approval within 18–36 months. The practices that are positioned to win in the post-approval market are the ones building their infrastructure now. Here is what that preparation looks like.
Tracking Clinical Outcomes in a Retatrutide Research Program: What Data to Collect and Why It Matters
The outcomes data you collect from your retatrutide research program is both a compliance requirement and a business asset. Here is what to track, how to track it, and how to use it.